NPPA and cardiac hypertrophy: On the one hand, the reduced expression of ANP and β-MHC in this study suggests that the reversal of cardiac hypertrophy after rapamycin treatment is not only due to the inhibition of mTOR but also fundamentally changes the pathological properties of the hypertrophy (such as the increase of wall stress).